Lipid Disorders: A Multidisciplinary Approach, Clinics Collections, 1e, (Clinics Collections)
Lipid Disorders: a Multidisciplinary Approach, Clinics Collections, 1e, (Clinics Collections)
1st Edition
Published on 15. October 2015
100 pages
978-0-323-42821-7 (ISBN)
Description
Clinics Collections: Lipid Disorders draws from Elsevier's robust Clinics Review Articles database to provide multidisciplinary teams, including general practitioners, cardiologists, endocrinologists, pathologists, cardiologists, rheumatologists, and hepatologists, with practical clinical advice and insights on this highly prevalent condition and its comorbidities. Clinics Collections: Lipid Disorders guides readers on how to apply current primary research findings on lipid disorders to everyday practice to help overcome challenges and complications, keep up with new and improved treatment methods, and improve patient outcomes.
. Areas of focus include lipids and biomarkers, lipids and pharmacotherapy, lipids and heart disease, lipids and chronic disease, lipids and pediatrics, lipids and women's health and special considerations.
. Each article begins with keywords and key points for immediate access to the most critical information.
. Articles are presented in an easy-to-digest and concisely worded format.
Elsevier's Clinics Collections provide concise reviews of today's most prevalent conditions and significant medical developments. Other Clinics Collections titles available include Type II Diabetes Mellitus, Asthma, Obesity, and Pain Management
More details
Other editions
Additional editions
Joel J. Heidelbaugh
Lipid Disorders: A Multidisciplinary Approach (Clinics Collections): Volume 5C
Volume 5c
Book
06/2015
Elsevier
€61.00
Shipment within 15-20 days
Content
- Front Cover
- Lipid Disorders: A Multidisciplinary Approach
- Copyright Page
- Table of Contents
- Contributors
- Preface
- Chapter 1. Biomarkers for Cholesterol Absorption and Synthesis in Hyperlipidemic Patients: Role for Therapeutic Selection
- INTRODUCTION
- BIOMARKERS OF CHOLESTEROL SYNTHESIS AND ABSORPTION
- CHOLESTEROL ABSORPTION AND SYNTHESIS MARKERS AS RISK FACTORS FOR CORONARY HEART DISEASE
- EFFECT OF LIPID-LOWERING DRUGS ON CHOLESTEROL SYNTHESIS AND ABSORPTION
- PROPOSED CLINICAL USE OF CHOLESTEROL ABSORPTION AND SYNTHESIS TESTS
- REFERENCES
- Chapter 2. Beginning to Understand High-Density Lipoproteins
- INTRODUCTION
- COMPOSITION OF THE HIGH-DENSITY LIPOPROTEIN PARTICLES
- OVERVIEW OF HIGH-DENSITY LIPOPROTEIN METABOLIC PATHWAYS: REVERSE CHOLESTEROL TRANSPORT
- ATHEROPROTECTIVE EFFECTS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL INDEPENDENT OF REVERSE CHOLESTEROL TRANSPORT
- HIGH-DENSITY LIPOPROTEIN DYSFUNCTION
- BEGINNING TO UNDERSTAND HIGH-DENSITY LIPOPROTEINS: WHY IS THE HIGH-DENSITY LIPOPROTEIN HYPOTHESIS SEEMINGLY FAILING?
- NONPHARMACOLOGIC STRATEGIES THAT POSITIVELY BENEFIT HIGH-DENSITY LIPOPROTEINS
- PHARMACOLOGIC THERAPY TO RAISE HIGH-DENSITY LIPOPROTEIN CHOLESTEROL CONCENTRATIONS
- SUMMARY
- REFERENCES
- Chapter 3. Cholesterol, Lipoproteins, High-sensitivity C-reactive Protein, and Other Risk Factors for Atherosclerosis
- INTRODUCTION
- PATHOGENESIS OF ATHEROSCLEROSIS
- THE ROLE OF LIPOPROTEINS
- TREATMENT GOALS
- LIPOPROTEIN ANALYSIS
- NOVEL BIOMARKERS
- HIGH-SENSITIVITY C-REACTIVE PROTEIN
- APOLIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2
- MYELOPEROXIDASE AND OXIDIZED LDL
- LIPOPROTEIN (A)
- GENETICS
- APOLIPOPROTEIN E POLYMORPHISMS
- APOLIPOPROTEIN (A) POLYMORPHISMS
- PROPROTEIN CONVERTASE SUBTILISIN/KINEXIN TYPE 9
- SUMMARY
- REFERENCES
- Chapter 4. Lipoprotein (a): An Important Cardiovascular Risk Factor and a Clinical Conundrum
- INTRODUCTION
- LIPOPROTEIN(a) STRUCTURE AND HETEROGENEITY
- GENETICS OF LPA
- LIPOPROTEIN(a) PRODUCTION AND METABOLISM
- PATHOGENIC MECHANISMS OF LIPOPROTEIN(a)
- ELEVATED PLASMA LIPOPROTEIN(a) CONCENTRATIONS AS A RISK FACTOR FOR VASCULAR DISEASE
- UTILITY OF LIPOPROTEIN(a) IN CLINICAL PRACTICE
- REFERENCES
- Chapter 5. Genetic Testing in Hyperlipidemia
- INTRODUCTION
- GENETIC TESTING IN FAMILIAL HYPERCHOLESTEROLEMIA
- OTHER POTENTIAL USES OF GENETIC TESTING
- GENETIC TESTING IN HYPERTRIGLYCERIDEMIA
- DISADVANTAGES OF GENETIC TESTING
- CURRENT TESTS AVAILABLE
- SUMMARY
- ACKNOWLEDGMENTS
- REFERENCES
- Chapter 6. Familial Hypercholesterolemia
- INTRODUCTION
- PATIENT EVALUATION
- TREATMENT
- SURGICAL THERAPY
- TREATMENT RESISTANCE/COMPLICATIONS
- DRUGS IN DEVELOPMENT
- SUMMARY
- REFERENCES
- Chapter 7. New Therapies for Reducing Low-Density Lipoprotein Cholesterol
- INTRODUCTION
- LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING AGENTS RECENTLY APPROVED
- LOW-DENSITY LIPOPROTEIN CHOLESTEROL-LOWERING AGENTS IN ADVANCED CLINICAL DEVELOPMENT
- SUMMARY
- REFERENCES
- Chapter 8. Combination Therapy with Statins: Who Benefits?
- INTRODUCTION
- QUESTIONING THE PARADIGM: UPDATED BLOOD CHOLESTEROL GUIDELINES
- STATINS AS FIRST-LINE THERAPY
- LIMITATIONS OF STATIN MONOTHERAPY
- SUMMARY
- REFERENCES
- Chapter 9. Lipid-Lowering Agents and Hepatotoxicity
- INTRODUCTION
- STATINS
- EZETIMIBE
- BILE ACID SEQUESTRANTS
- NIACIN
- FIBRATES
- SUMMARY
- REFERENCES
- Chapter 10. Screening Strategies for Cardiovascular Disease in Asymptomatic Adults
- EPIDEMIOLOGY AND RISK FACTORS
- GLOBAL RISK ASSESSMENT TOOLS
- DESCRIPTION OF COMMONLY USED SCREENING METHODS
- EVIDENCE FOR RISK ASSESSMENT AND SCREENING
- CVD PREVENTION AND SCREENING RECOMMENDATIONS
- CURRENT PRACTICE PATTERNS
- IMPACT OF CHANGES WITHIN HEALTH CARE
- SUMMARY
- ACKNOWLEDGMENTS
- REFERENCES
- Chapter 11. The 2013 American College of Cardiology/American Heart Association Guidelines on Treating Blood Cholesterol and Assessing Cardiovascular Risk: A Busy Practitioner's Guide
- PARADIGM SHIFT FROM TREAT-TO-TARGET TO INTENSITY OF STATIN THERAPY
- INCREASE IN ELIGIBILITY FOR STATIN THERAPY
- RISK ASSESSMENT EQUATIONS
- DEVELOPING THE NEW AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION POOLED COHORT 10-YEAR RISK EQUATION
- ASSESSING THE NEW AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION POOLED COHORT 10-YEAR RISK EQUATION
- RATIONALE FOR CONSTRUCTING MODELS TO ASSESS THE LONG-TERM/LIFETIME RISK FOR A FIRST HARD ATHEROSCLEROTIC CARDIOVASCULAR DISEASE EVENT
- OTHER MEASUREMENTS
- STATIN SAFETY
- SUMMARY
- REFERENCES
- Chapter 12. New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk: A Comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia
- THE 2013 AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL
- THE 2014 NATIONAL LIPID ASSOCIATION RECOMMENDATIONS FOR PATIENT-CENTERED MANAGEMENT OF DYSLIPIDEMIA
- COMPARISON AND CONTRASTS OF THE NEW GUIDELINES
- REFERENCES
- Chapter 13. Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
- EPIDEMIOLOGY AND PATHOPHYSIOLOGY OF HYPERTRIGLYCERIDEMIA
- HYPERTRIGLYCERIDEMIA VERSUS ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ASSOCIATION AND POTENTIAL CAUSATION
- EFFECTS OF TRIGLYCERIDE LEVEL-LOWERING MEDICATIONS ON ATHEROSCLEROTIC CARDIOVASCULAR DISEASE EVENTS: RANDOMIZED CLINICAL TRIALS
- TREATMENT RECOMMENDATIONS FOR HYPERTRIGLYCERIDEMIA
- REFERENCES
- Chapter 14. Lipid-Modifying Treatments for Heart Failure: Is Their Use Justified?
- INTRODUCTION
- FIBRATES
- OMEGA-3 FATTY ACIDS OR POLYUNSATURATED FATTY ACIDS
- STATINS (3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE INHIBITORS)
- GISSI-HF
- CORONA
- PEARL
- SUMMARY
- REFERENCES
- Chapter 15. Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels
- INTRODUCTION
- EPIDEMIOLOGY AND SIGNIFICANCE
- CURRENT GUIDELINES FOR POST-MYOCARDIAL INFARCTION MANAGEMENT AND SUPPORTING EVIDENCE
- MANAGING SERUM LIPIDS IN THE CONTEMPORARY ERA
- SUMMARY
- REFERENCES
- Chapter 16. Lifestyle Intervention: Nutrition Therapy and Physical Activity
- INTRODUCTION
- NONPHARMACOLOGIC TREATMENT OPTIONS: LIFESTYLE INTERVENTION: NUTRITION THERAPY
- NONPHARMACOLOGIC TREATMENT OPTIONS: LIFESTYLE INTERVENTION: PHYSICAL ACTIVITY
- TREATMENT RESISTANCE AND COMPLICATIONS: NUTRITION THERAPY AND PHYSICAL ACTIVITY
- EVALUATION OF OUTCOME: NUTRITION THERAPY AND PHYSICAL ACTIVITY
- LONG-TERM RECOMMENDATIONS: CLINICAL PRIORITIES: NUTRITION THERAPY AND PHYSICAL ACTIVITY
- FUTURE CONSIDERATIONS/SUMMARY
- REFERENCES
- Chapter 17. Statins and Diabetes
- INTRODUCTION
- CLINICAL TRIAL EVIDENCE REGARDING STATIN USE AND DIABETES
- SUMMARY
- REFERENCES
- Chapter 18. Lipid-Associated Rheumatologic Syndromes
- INTRODUCTION
- LIPOPROTEINS AND THE CURRENT CLASSIFICATION OF DYSLIPIDEMIA
- HYPERLIPIDEMIA AND TENDINOPATHY
- HYPERLIPIDEMIA-ASSOCIATED ARTHRITIS
- LIPID LIQUID CRYSTAL ARTHRITIS
- HYPERLIPIDEMIA AND GOUT
- RHEUMATOLOGIC DISEASE INDUCED BY LIPID-LOWERING THERAPY
- SUMMARY
- REFERENCES
- Chapter 19. Fatty Acid Requirements in Preterm Infants and Their Role in Health and Disease
- INTRODUCTION
- PLACENTAL TRANSFER AND FETAL ACQUISITION OF LONG-CHAIN POLYUNSATURATED FATTY ACIDS
- HEALTH CONSEQUENCES OF ALTERED LCPUFA LEVELS IN PRETERM INFANTS
- EVIDENCE SUPPORTING THE ROLE OF LCPUFAS IN OPTIMIZING HEALTH IN PRETERM INFANTS
- CHALLENGES IN DELIVERING LCPUFAS TO PRETERM INFANTS
- FUTURE DIRECTIONS
- SUMMARY
- REFERENCES
- Chapter 20. Pediatric Lipid Management: An Earlier Approach
- INTRODUCTION
- THE GUIDELINES: FRAMEWORK AND SYNOPSIS
- CHALLENGES TO THE LIPID MANAGEMENT GUIDELINES
- SUMMARY
- ADDITIONAL RESOURCES
- REFERENCES
- Chapter 21. Dyslipidemia in Pregnancy
- INTRODUCTION
- CHOLESTEROL AND FETAL DEVELOPMENT
- PREVALENCE OF CARDIOVASCULAR DISEASE RISK FACTORS
- FETAL CONSIDERATIONS
- MATERNAL CONSIDERATIONS
- POSTPARTUM CONSIDERATIONS
- REFERENCES
- Chapter 22. Women's Health Considerations for Lipid Management
- INTRODUCTION
- DETECTION, MANAGEMENT, AND TREATMENT OF DYSLIPIDEMIA IN PREGNANCY
- LONG-TERM IMPLICATIONS OF COMPLICATIONS IN PREGNANCY
- SCREENING FOR ASSOCIATED DYSLIPIDEMIA IN POLYCYSTIC OVARIAN SYNDROME
- TREATMENT OF DYSLIPIDEMIA IN POLYCYSTIC OVARIAN SYNDROME
- DYSLIPIDEMIA TREATMENT AND UNIQUE CHALLENGES FOR WOMEN WITH POLYCYSTIC OVARIAN SYNDROME
- LIPID CHANGES WITH DIFFERENT FORMS OF CONTRACEPTION
- NON-COMBINED ORAL CONTRACEPTIVE METHODS
- MENOPAUSE TRANSITION
- CURRENT RECOMMENDATIONS FOR HORMONE THERAPY
- REFERENCES
- Chapter 23. Dyslipidemia and Cardiovascular Risk in Human Immunodeficiency Virus Infection
- INTRODUCTION
- FACTORS OTHER THAN DYSLIPIDEMIA MAY CONTRIBUTE TO ACCELERATED ATHEROSCLEROSIS IN HIV INFECTION
- DYSLIPIDEMIA AND CVD IN HIV INFECTION
- LIPID CHANGES DURING TREATED HIV DISEASE MAY CONTRIBUTE TO IMMUNE ACTIVATION IN HIV INFECTION
- MANAGEMENT OF LIPID DISORDERS
- SUMMARY
- REFERENCES
- Chapter 24. Coronary Artery Calcium Scanning: The Key to the Primary Prevention of Coronary Artery Disease
- INTRODUCTION
- THE CORONARY ARTERY CALCIUM SCAN
- THE PROGNOSTIC DATA
- PATIENT SUBGROUPS
- CORONARY ARTERY CALCIUM SCANNING AND ADHERENCE
- SERIAL CORONARY ARTERY CALCIUM SCANNING
- POST-CORONARY ARTERY CALCIUM SCANNING TESTING
- CORONARY ARTERY CALCIUM SCANNING AND THE 2013 GUIDELINES
- CORONARY ARTERY CALCIUM SCANNING LIMITATIONS
- SUMMARY
- REFERENCES
- Chapter 25. Dyslipidemia in Special Ethnic Populations
- INTRODUCTION
- PREVALENCE OF DYSLIPIDEMIA SUBTYPES AMONG SPECIAL RACIAL/ETHNIC GROUPS
- DYSLIPIDEMIA-RELATED MORTALITY IN SPECIAL RACIAL/ETHNIC GROUPS
- TREATMENT OF DYSLIPIDEMIA
- SUMMARY
- REFERENCES
- Back Cover
